{"id":483109,"date":"2021-04-28T07:08:25","date_gmt":"2021-04-28T11:08:25","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/alkermes-announces-two-abstracts-accepted-for-presentation-at-2021-american-society-of-clinical-oncology-annual-meeting\/"},"modified":"2021-04-28T07:08:25","modified_gmt":"2021-04-28T11:08:25","slug":"alkermes-announces-two-abstracts-accepted-for-presentation-at-2021-american-society-of-clinical-oncology-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/alkermes-announces-two-abstracts-accepted-for-presentation-at-2021-american-society-of-clinical-oncology-annual-meeting\/","title":{"rendered":"Alkermes Announces Two Abstracts Accepted for Presentation at 2021 American Society of Clinical Oncology Annual Meeting"},"content":{"rendered":"
\n

– Two Posters to Include Data Updates From ARTISTRY-1 and ARTISTRY-2 Clinical Trials Evaluating Immuno-Oncology Candidate Nemvaleukin Alfa –<\/h2>\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n DUBLIN<\/span>, April 28, 2021<\/span> \/PRNewswire\/ — Alkermes plc<\/a>\u00a0(Nasdaq: ALKS) today announced the acceptance of two abstracts related to nemvaleukin alfa (nemvaleukin), the company’s novel, investigational engineered interleukin-2 (IL-2) variant immunotherapy, at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place virtually June 4-8, 2021<\/span>. New data from the phase 1\/2 ARTISTRY-1 clinical trial evaluating the tolerability and efficacy of nemvaleukin administered intravenously as a monotherapy and in combination with pembrolizumab (KEYTRUDA\u00ae<\/sup>) will be shared in a poster discussion session. In addition, data supporting the recommended phase 2 dose (RP2D) for nemvaleukin administered subcutaneously from the phase 1\/2 ARTISTRY-2 clinical trial will be shared in a separate poster. <\/p>\n

Details of the presentations are as follows:
Abstract:<\/b> 2513
Title:<\/b> ARTISTRY-1: Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors
Presenter:<\/b>Valentina Boni<\/span>, M.D., Ph.D., Medical Oncologist and Principal Investigator, START Madrid<\/span> at Centro Integral Oncol\u00f3gico Clara Campal
Presentation Date\/Time: <\/b>The on-demand poster discussion session will take place on June 4, 2021<\/span> from 9:00 \u2013 10:00 a.m. ET<\/span>. <\/p>\n

\n Abstract: <\/b>2552
Title:<\/b> Selection of the recommended phase 2 dose (RP2D) for subcutaneous nemvaleukin alfa: ARTISTRY-2
Presenter:<\/b>Omid Hamid<\/span>, M.D., Chief of Research and Immunotherapy, The Angeles Clinic and Research Institute
Presentation Date: <\/b>The poster presentation will\u00a0be available on-demand to attendees beginning June 4, 2021<\/span>.<\/p>\n

\n
\n About Nemvaleukin alfa (“nemvaleukin”)
<\/u>
\n <\/b>Nemvaleukin is an investigational, novel, engineered fusion protein comprised of modified interleukin-2 (IL-2) and the high affinity IL-2 alpha receptor chain, designed to selectively expand tumor-killing immune cells while avoiding the activation of immunosuppressive cells by preferentially binding to the intermediate-affinity IL-2 receptor complex. The selectivity of nemvaleukin is designed to leverage the proven anti-tumor effects of existing IL-2 therapy while mitigating certain limitations.<\/p>\n

\n
\n About the ARTISTRY Clinical Development Program<\/u>
\n <\/b>\u00a0
ARTISTRY is an Alkermes-sponsored clinical development program evaluating nemvaleukin alfa as a potential immunotherapy for cancer. The ARTISTRY program is comprised of multiple clinical trials evaluating intravenous and subcutaneous dosing of nemvaleukin, both as a monotherapy and in combination with the anti-PD-1 therapy KEYTRUDA\u00ae<\/sup> (pembrolizumab) in patients with advanced solid tumors. Ongoing trials include: ARTISTRY-1<\/a>, ARTISTRY-2<\/a>, ARTISTRY-3<\/a>\u00a0and ARTISTRY-6<\/a>.<\/p>\n

\n
\n About\u00a0Alkermes plc
<\/u>
\n <\/b>Alkermes plc\u00a0is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders and cancer. Headquartered in\u00a0Dublin, Ireland,\u00a0Alkermes plc\u00a0has an R&D center in\u00a0Waltham,\u00a0Massachusetts; a research and manufacturing facility in Athlone,\u00a0Ireland; and a manufacturing facility in\u00a0Wilmington,\u00a0Ohio. For more information, please visit Alkermes’\u00a0<\/b>website at\u00a0<\/b>www.alkermes.com<\/a><\/u><\/b>.<\/b><\/p>\n

KEYTRUDA\u00ae<\/sup>\u00a0is a registered trademark of\u00a0Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.,\u00a0Kenilworth, NJ, USA.<\/p>\n

\n Alkermes Contacts:\u00a0
<\/u>For Investors: Sandy Coombs<\/span>, +1 781 609 6377
For Media: Sourojit Bhowmick, Ph.D. +1 781 609 6397<\/p>\n

\n

\n
\n \"Alkermes
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\u00a0<\/p>\n

<\/div>\n

\n \"Cision\" View original content to download multimedia:http:\/\/www.prnewswire.com\/news-releases\/alkermes-announces-two-abstracts-accepted-for-presentation-at-2021-american-society-of-clinical-oncology-annual-meeting-301278601.html<\/a><\/p>\n

SOURCE Alkermes plc<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

– Two Posters to Include Data Updates From ARTISTRY-1 and ARTISTRY-2 Clinical Trials Evaluating Immuno-Oncology Candidate Nemvaleukin Alfa – PR Newswire DUBLIN, April 28, 2021 \/PRNewswire\/ — Alkermes plc\u00a0(Nasdaq: ALKS) today announced the acceptance of two abstracts related to nemvaleukin alfa (nemvaleukin), the company’s novel, investigational engineered interleukin-2 (IL-2) variant immunotherapy, at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place virtually June 4-8, 2021. New data from the phase 1\/2 ARTISTRY-1 clinical trial evaluating the tolerability and efficacy of nemvaleukin administered intravenously as a monotherapy and in combination with pembrolizumab (KEYTRUDA\u00ae) will be shared in a poster discussion session. In addition, data supporting the recommended phase 2 dose (RP2D) for nemvaleukin administered subcutaneously from the phase … <\/p>\n

Continue reading “Alkermes Announces Two Abstracts Accepted for Presentation at 2021 American Society of Clinical Oncology Annual Meeting”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-483109","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAlkermes Announces Two Abstracts Accepted for Presentation at 2021 American Society of Clinical Oncology Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alkermes-announces-two-abstracts-accepted-for-presentation-at-2021-american-society-of-clinical-oncology-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alkermes Announces Two Abstracts Accepted for Presentation at 2021 American Society of Clinical Oncology Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"– Two Posters to Include Data Updates From ARTISTRY-1 and ARTISTRY-2 Clinical Trials Evaluating Immuno-Oncology Candidate Nemvaleukin Alfa – PR Newswire DUBLIN, April 28, 2021 \/PRNewswire\/ — Alkermes plc\u00a0(Nasdaq: ALKS) today announced the acceptance of two abstracts related to nemvaleukin alfa (nemvaleukin), the company’s novel, investigational engineered interleukin-2 (IL-2) variant immunotherapy, at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place virtually June 4-8, 2021. New data from the phase 1\/2 ARTISTRY-1 clinical trial evaluating the tolerability and efficacy of nemvaleukin administered intravenously as a monotherapy and in combination with pembrolizumab (KEYTRUDA\u00ae) will be shared in a poster discussion session. In addition, data supporting the recommended phase 2 dose (RP2D) for nemvaleukin administered subcutaneously from the phase … Continue reading "Alkermes Announces Two Abstracts Accepted for Presentation at 2021 American Society of Clinical Oncology Annual Meeting"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/alkermes-announces-two-abstracts-accepted-for-presentation-at-2021-american-society-of-clinical-oncology-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-28T11:08:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/616416\/Alkermes_plc_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alkermes-announces-two-abstracts-accepted-for-presentation-at-2021-american-society-of-clinical-oncology-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alkermes-announces-two-abstracts-accepted-for-presentation-at-2021-american-society-of-clinical-oncology-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Alkermes Announces Two Abstracts Accepted for Presentation at 2021 American Society of Clinical Oncology Annual Meeting\",\"datePublished\":\"2021-04-28T11:08:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alkermes-announces-two-abstracts-accepted-for-presentation-at-2021-american-society-of-clinical-oncology-annual-meeting\\\/\"},\"wordCount\":524,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alkermes-announces-two-abstracts-accepted-for-presentation-at-2021-american-society-of-clinical-oncology-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/616416\\\/Alkermes_plc_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alkermes-announces-two-abstracts-accepted-for-presentation-at-2021-american-society-of-clinical-oncology-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alkermes-announces-two-abstracts-accepted-for-presentation-at-2021-american-society-of-clinical-oncology-annual-meeting\\\/\",\"name\":\"Alkermes Announces Two Abstracts Accepted for Presentation at 2021 American Society of Clinical Oncology Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alkermes-announces-two-abstracts-accepted-for-presentation-at-2021-american-society-of-clinical-oncology-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alkermes-announces-two-abstracts-accepted-for-presentation-at-2021-american-society-of-clinical-oncology-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/616416\\\/Alkermes_plc_Logo.jpg\",\"datePublished\":\"2021-04-28T11:08:25+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alkermes-announces-two-abstracts-accepted-for-presentation-at-2021-american-society-of-clinical-oncology-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alkermes-announces-two-abstracts-accepted-for-presentation-at-2021-american-society-of-clinical-oncology-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alkermes-announces-two-abstracts-accepted-for-presentation-at-2021-american-society-of-clinical-oncology-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/616416\\\/Alkermes_plc_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/616416\\\/Alkermes_plc_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alkermes-announces-two-abstracts-accepted-for-presentation-at-2021-american-society-of-clinical-oncology-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alkermes Announces Two Abstracts Accepted for Presentation at 2021 American Society of Clinical Oncology Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alkermes Announces Two Abstracts Accepted for Presentation at 2021 American Society of Clinical Oncology Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/alkermes-announces-two-abstracts-accepted-for-presentation-at-2021-american-society-of-clinical-oncology-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Alkermes Announces Two Abstracts Accepted for Presentation at 2021 American Society of Clinical Oncology Annual Meeting - Market Newsdesk","og_description":"– Two Posters to Include Data Updates From ARTISTRY-1 and ARTISTRY-2 Clinical Trials Evaluating Immuno-Oncology Candidate Nemvaleukin Alfa – PR Newswire DUBLIN, April 28, 2021 \/PRNewswire\/ — Alkermes plc\u00a0(Nasdaq: ALKS) today announced the acceptance of two abstracts related to nemvaleukin alfa (nemvaleukin), the company’s novel, investigational engineered interleukin-2 (IL-2) variant immunotherapy, at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place virtually June 4-8, 2021. New data from the phase 1\/2 ARTISTRY-1 clinical trial evaluating the tolerability and efficacy of nemvaleukin administered intravenously as a monotherapy and in combination with pembrolizumab (KEYTRUDA\u00ae) will be shared in a poster discussion session. In addition, data supporting the recommended phase 2 dose (RP2D) for nemvaleukin administered subcutaneously from the phase … Continue reading \"Alkermes Announces Two Abstracts Accepted for Presentation at 2021 American Society of Clinical Oncology Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/alkermes-announces-two-abstracts-accepted-for-presentation-at-2021-american-society-of-clinical-oncology-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-28T11:08:25+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/616416\/Alkermes_plc_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alkermes-announces-two-abstracts-accepted-for-presentation-at-2021-american-society-of-clinical-oncology-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alkermes-announces-two-abstracts-accepted-for-presentation-at-2021-american-society-of-clinical-oncology-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Alkermes Announces Two Abstracts Accepted for Presentation at 2021 American Society of Clinical Oncology Annual Meeting","datePublished":"2021-04-28T11:08:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alkermes-announces-two-abstracts-accepted-for-presentation-at-2021-american-society-of-clinical-oncology-annual-meeting\/"},"wordCount":524,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alkermes-announces-two-abstracts-accepted-for-presentation-at-2021-american-society-of-clinical-oncology-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/616416\/Alkermes_plc_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alkermes-announces-two-abstracts-accepted-for-presentation-at-2021-american-society-of-clinical-oncology-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/alkermes-announces-two-abstracts-accepted-for-presentation-at-2021-american-society-of-clinical-oncology-annual-meeting\/","name":"Alkermes Announces Two Abstracts Accepted for Presentation at 2021 American Society of Clinical Oncology Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alkermes-announces-two-abstracts-accepted-for-presentation-at-2021-american-society-of-clinical-oncology-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alkermes-announces-two-abstracts-accepted-for-presentation-at-2021-american-society-of-clinical-oncology-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/616416\/Alkermes_plc_Logo.jpg","datePublished":"2021-04-28T11:08:25+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alkermes-announces-two-abstracts-accepted-for-presentation-at-2021-american-society-of-clinical-oncology-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/alkermes-announces-two-abstracts-accepted-for-presentation-at-2021-american-society-of-clinical-oncology-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alkermes-announces-two-abstracts-accepted-for-presentation-at-2021-american-society-of-clinical-oncology-annual-meeting\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/616416\/Alkermes_plc_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/616416\/Alkermes_plc_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alkermes-announces-two-abstracts-accepted-for-presentation-at-2021-american-society-of-clinical-oncology-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Alkermes Announces Two Abstracts Accepted for Presentation at 2021 American Society of Clinical Oncology Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/483109","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=483109"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/483109\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=483109"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=483109"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=483109"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}